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Cultured human umbilical endothelial cells were incubated with lipoxins and their ability to generate prostacyclin (PGI,) 
was assessed and compared to that induced by either leukotriene C, or an ionophore of divalent cations (A-23,187). When 
exposed to either lipoxin 4, lipoxin B4, or ‘I-cis.1 I-truns-lipoxin 4, endothelial cells generated prostacyclin detected 
as 6-keto-PGF,,. Of the lipoxins examined, ‘I-c&l I-trans-lipoxin A., proved to be the most effective with PGI, production 
twice that induced by equimolar amounts of A-23,187 (5 PM). On a molar basis, lipoxin A., and lipoxin B4 were less 
potent than leukotriene C, although they were more efficacious. When either lipoxin A., or lipoxin B4 was added to cells 
simultaneously with leukotriene C,, the formation of prostacyclin was greater than that induced by leukotriene C, alone. 
During the time course of exposure to lipoxins (O-20 min, 37”C), cultured endothelial cells did not further transform 
these compounds via o-oxidation as determined by reverse-phase HPLC. These data indicate that lipoxins can stimulate 
PGI, generation by human endothelial cells. Moreover, they suggest a role for these lipoxygenase products of arachidonic 
acid in the regulation of hernostasis, inflammation and vascular eactivity. 
Arachidonic acid; Lipoxygenase product 
1. INTRODUCTION 
Endothelial cells, in addition to serving as the in- 
terface between blood and the surrounding tissue, 
can influence vascular and blood cell physiology 
through a variety of mechanisms. For example, 
upon activation these cells can release and ox- 
ygenate arachidonic acid to generate prostacyclin 
(PGIz), which can affect the function of smooth 
muscle cells, platelets, and neutrophils. A variety 
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of other endogenous products of arachidonate 
metabolism including Slipoxygenase-derived 
leukotriene Cd and leukotriene Dq can lead to the 
generation and release of PGIz by human en- 
dothelial cells [ 11. 
Interactions between the 5- and 1Slipoxygenase 
can lead to the generation of lipoxins [2-41. Lipox- 
in A4 (LX&) and lipoxin Bq (LXB4) each display 
unique profiles of action which are distinct from 
those of other oxygenated products of arachidonic 
acid [3-81. Among its activities, LX& possesses a
vasodilatory effect. In particular, LX& stimulates 
dilation of arterioles in vivo with vessels of the 
hamster cheek pouch [3,5] and induces glomerular 
hyperperfusion and hyperfiltration in renal micro- 
circulation of the rat [6]. LX& also induces 
changes in single nephron glomerular filtration rate 
and plasma flow rate which are due to selective 
relaxation of pre-glomerular esistance vessels [6]. 
Upon systematic administration, however, both 
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LX& and LXB4 have been shown to cause 
endothelial-dependent relaxation in vascular 
tissues from a variety of species [8]. Here, we 
report that LX&, LXB4, and the recently iden- 
tified 7-cis-l l-trans-LX& [4] stimulate the forma- 
tion of prostacyclin in cultured human endothelial 
cells. 
2. MATERIALS AND METHODS 
2.1. Materials 
LX&, LXB4, and I-c&11-trans-LX& were prepared by 
total organic synthesis as described [4,9] and tested here as their 
free acids. Leukotriene Cq (LTC4) was from Biomol Research 
Laboratories, Inc., Plymouth Meeting, PA. All solvents were 
from Burdick and Jackson (HPLC grade), Muskegon, MI. 
2.2. Cell preparations and incubation 
Human umbilical vein endothelial cells (HUVEC) were 
isolated from two to five normal term cord segments, pooled 
and established in primary culture using Medium 199 (M199, 
M.A. Bioproducts, Bethesda, MD) with 20% fetal calf serum 
(FCS, Gibco, Grand Island, NY) and antibiotics as previously 
described [lo]. HUVEC cultures were serially passaged (I:3 split 
ratio) and maintained using M199/20% FCS supplemented with 
endothelial cell growth factor (50 rg/ml; Biomedical 
Technologies, Inc., Stoughton, MA) and porcine intestinal 
heparin (100 pg/ml; Sigma, St. Louis, MO) in Costar tissue 
culture flasks (75 cm’, Data Packaging Corp., Cambridge, MA) 
coated with 0.1% gelatin (Bactogelatin 0143-02, Difco, Detroit, 
MI). For experimental use, HUVEC strains were replicate 
plated (passage levels 2-3) in microtiter wells (Costar Inc., Cam- 
bridge, MA) or 100 mm plastic dishes precoated with 0.1% 
gelatin. The confluence of endothelial cell layers was confirmed 
under microscopy before the addition of each compound. 
5 min prior to the addition of the compounds, medium 
(M199) was decanted and Dulbecco’s phosphate buffered saline 
(PBS) was added (pH 7.45, 37°C). After 5 min of incubation, 
either LX& (0.5, 1, and 5 FM), LTC4 (0.05, 0.5 and 5 pM), 
7-cis, 1 I-trans-LX& (5 CM), or A-23, 187 (5 ,QM) were added to 
individual wells. The concentration and integrity of each of the 
eicosanoids were confirmed by UV analysis immediately before 
each experiment. In several experiments the cyclooxygenase in- 
hibitor, ibuprofen (80 pg/ml), was incubated with cells (1 min, 
37°C) prior to the addition of stimuli. 
Following incubation (20 min, 37”C), aliquots (500$) of the 
supernatants were removed and immediately placed on ice for 
determination of 6-keto-PGFi, by radioimmunoassay. Next, 
cold EtOH (1 ml) was added to the remaining incubations and 
the mixtures were taken for further analysis by HPLC. In 
parallel experiments, lipoxins (5 PM) were added to cells and in- 
cubated (20 min, 37°C) vide supra and cell viability was assessed 
by their ability to exclude trypan blue. In all reported ex- 
periments the viability was > 98%. Radioimmunoassay for 
6-keto-PGFi, was performed by methods previously described 
191. 
2.3. Analytical methods 
Incubations were stopped by addition of EtOH (1 ml), stored 
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at - 20°C and analyzed for lipoxygenase products as described 
[4]. Briefly, samples were centrifuged at 800 x g for 15 min, 
supernatants were removed and pellets were washed with 
MeOH. MeOH- and EtOH-containing fractions were combined 
and organic solvents were removed by rotational evaporation. 
Next, samples were suspended in water, acidified, and loaded 
into Sep-pak Cl 8 reverse-phase cartridges (Waters Associates, 
Milford, MA). The cartridges were washed with water (10 ml) 
and hexane (10 ml), and the products were eluted from the col- 
umn with methyl formate (10 ml). Samples were examined for 
UV absorbing materials prior to injection into a RP-HPLC 
system. The system consisted of an LKB dual-pump gradient 
HPLC equipped with a Nova-Pak Cl8 column (3.9 mm x 7.5 
mm), injector, and solvent controller (LKB, Bromma, Sweden). 
The column was eluted with MeGH/HzO/acetic acid 
(68:32:0.01) as solvent at a flow rate of 0.39 ml/min with an in- 
itial pressure of approximately 25 Bar. This HPLC system was 
equipped with a photodiode array rapid spectral detector linked 
to an AT&T PC6300, and post-HPLC run analyses were per- 
formed utilizing a 2140-202 Wavescan program (Bromma, 
Sweden) and Nelson Analytical 3000 series chromatography 
data system (Paramus, NJ). Products were quantitated from 
their UV spectra (220-340 nm) following HPLC where baselines 
between eluting chromophores were achieved by computer- 
aided manipulation. PGBs was included prior to extraction as 
an internal standard. UV spectra which were not recorded on- 
line during HPLC were recorded with a Hewlett-Packard model 
8452 photodiode array spectrophotometer. 
3. RESULTS 
When added to endothelial cells in culture, each 
of the lipoxins stimulated PGI2 formation as 
monitored by the detection of 6-keto-PGFr, levels. 
All values were normalized to paired incubations in 
which the cells were exposed to A-23,187 (5 PM). 
The mean level of 6-keto-PGFr, detected in 
response to A-23,187 was 4.3 + 0.5 pmol/ml 
(n = 7 separate preparations of cultured endo- 
thelial cells; mean f SEM). It can be seen that 
both LX& and LXB4 at a concentration of 5 gM 
caused a significantly greater release of PGIz than 
vehicle-treated cells (P<O.O5). Although a tenden- 
cy for LX&-induced PGI2 production occurred at 
a concentration of 1 pM, the value of 0.44 was not 
statistically significant when compared to vehicle 
control levels. At lower concentrations of LX& 
(0.5 PM) and LXB4 (1 .OpM, 0.5 PM), mean values 
were not greater than 0.20 and were also not 
significantly different from those obtained with the 
vehicle. Lipoxin &-induced formation of (i-keto- 
PGFr, was completely inhibited by prior treatment 
of the cells with the cycle-oxygenase inhibitor 
ibuprofen. Results of previous studies have shown 
that leukotrienes can stimulate the generation of 
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Fig. 1. Summary of lipoxin-induced 6-keto-PGFt, detected in supernates from cultured human umbilical endothelial cells. Bars and 
brackets represent means f SE, respectively. Numbers within bars represent number of different endothelial cell cultures studied. 
* P< 0.05 from vehicle control (ethanol); ** PC 0.01 from vehicle control; *** P<O.O5 from paired vehicle controls. Mean value for 
PGFI, in response to A-23,187 (5 PM) was 4.3 f 0.5 pmol/ml (n = 7, mean f SE). 
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Fig.2. Effect of simultaneous addition of LTCb and lipoxins to human umbilical endothelial cells. Bars and brackets represent means 
and SE, respectively. Numbers below bars represent number of different endothelial cell cultures studied. NS, no significant difference. 
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PGIz [l]. In the present study, LTG (0.5 PM) also 
caused an increase in the levels of PGI2. However, 
increasing the LTG concentration to 5 PM failed 
to significantly change the level of 6-keto-PGFl, 
detected. The recently identified human neutro- 
Phil-derived product 7-c& 11 -trans-LX& [4] in- 
duced almost twice the amount of PGI2 production 
as observed with maximal ionophore stimulation 
(fig.1). Thus, this compound was the most potent 
of the lipoxins examined. 
The effect of combined addition of lipoxins and 
LTC4 at maximal stimulatory concentrations is 
given in fig.2. In these experiments, the levels of 
PGI2 generated in response to maximal stimulatory 
concentrations of LTD4 were significantly less than 
those obtained with combined LTG and lipoxin 
I I I 1 
0 IO 20 30 
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Fig.3. RP-HPLC chromatograph of lipoxin &after incubation 
(20 min, 37°C) with endothelial cells. Following extraction, 
samples were injected into a RP-HPLC, Nova-Pak Cl8 
(2.9 mm x 7.5 cm) equipped with a rapid spectral detector. 
Post-HPLC analyses were performed with a Wavescan 2140-202 
program and a Nelson Analytical 3000 series chromatography 
data system. The elution times for LX&, all-tmns LX&, and 
PGBz are 6.7, 5.6 and 9.4 min, respectively. w-Oxidative pro- 
ducts were not observed. In the insert, the topogram for LX& 
is depicted. It can be seen that LX& retained its tetraene 
chromatogram with a h,,, at 300 nm and shoulders at 287 and 
3 15 nm. The chromatogram is representative of six separate in- 
cubations (n = 3 with separate preparations of human endo- 
thelial cells and La and n = 3 with LXB4). 
(LXB4 or LX&) [P value < 0.051. Although there 
was a tendency for the combined agonists to cause 
greater stimulation than lipoxins alone, these 
values did not prove to be statistically significant. 
Next, to determine if lipoxins were transformed 
by endothelial cells and to determine if their 
transformation products were responsible for 
stimulating PGI2 formation, the products obtained 
following incubation were extracted and analyzed 
by HPLC. A representative chromatogram of 
LX& obtained following incubation (20 min, 
37°C) with endothelial cells is shown in fig.3. 
LX& remained intact following exposure to en- 
dothelial cells. Its retention time was identical to 
that of the synthetic standard, and it retained its 
tetraene chromophore. w-Oxidative products of 
LX& were not observed. However, small amounts 
of its all-trans-isomer (l l-trans-LXA4) were 
detected. Previous results indicate that 15-20% of 
LX& is converted to its all-trans isomer following 
extraction and HPLC [14]. The levels of all-truns 
LX& obtained following incubation without en- 
dothelial cells, extraction and HPLC indicated that 
the transformation of LXA_I to all-trans-LX& was 
not a metabolic event in human endothelial cells. 
Similar studies with LXB4 showed that it too was 
not metabolically transformed by endothelial cells 
during this time course. 
4. DISCUSSION 
A number of physiologic actions of the lipoxins 
have been described over the last four years (for 
reviews, see [17]). These include inhibition of 
natural killer cell activity [12], endothelial- 
dependent relaxation of aortic strips [8], 
mesenteric vein constriction [7], contraction of 
lung parenchyma strips in a variety of species [8], 
vasodilation of vessels of the hamster cheek pouch 
[5], reduction in renal afferent arterial resistance 
[6], chemotaxis with human neutrophils [ 151 and 
activation of isolated protein kinase C [l I]. The 
present results demonstrate that lipoxins can also 
induce PGI2 production by human umbilical en- 
dothelial cells. These results with endothelial cells 
are consistent with recent findings which document 
that both lipoxin _A4 and lipoxin B4 provoke an 
endothelial-dependent relaxation of aortic vascular 
strips from a variety of species [8]. Lipoxin A4 has 
also been demonstrated to induce vasodilation in 
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the hamster cheek pouch and selective relaxation of 
renal afferent arteries [5,6]. These in vivo observa- 
tions would suggest hat the mechanism reported 
here, namely lipoxin-induced prostacyclin genera- 
tion by endothelium, can play a role in the intact 
circulatory system. In addition, lipoxins may also 
be involved in the release of other endothelial- 
derived relaxing factors [20,21] such as nitric oxide 
[22]. On the other hand, the vasoconstriction of the 
splanchnic circulation observed upon systemic in- 
jection of lipoxin A4 and lipoxin B4 [7] may be 
mediated through their ability to generate other 
vasoactive agents such as thromboxane [16,17]. 
Taken together these findings suggest multiple 
roles for lipoxins in the regulation of vascular tone. 
7-cis, 1 1-truns-LX& is a recently described 
lipoxin that was first isolated from human 
neutrophils [4]. The biological responses evoked by 
lipoxin & and lipoxin B4 have proven to be highly 
stereospecific (reviewed in [ 171). For example, with 
airway smooth muscle changes in either orientation 
of alcohol groups or the geometry of double bonds 
in LX& can delete or diminish activity, respective- 
ly [4,14-191. When the actions of 7-cis,l l-trans- 
LX& were compared to those of LxA4 for con- 
tractile activity in the guinea pig lung, 
7-cis, 1 I-trans-LX& proved to be 10 times less ac- 
tive than LX& [4]. In contrast, the present results 
indicate that 7-cis, 1 1-trans-LX& is more active 
than LX& in stimulating the formation of PGIz by 
human endothelial cells (fig.1). Taken together, 
these findings provided further evidence indicating 
that the biological actions of lipoxins are highly 
stereospecific, since these two compounds 
(7-cis, 1 I-trans-LX& and LX&) differ only in the 
geometry of two double bonds. In this respect, it is 
of interest to note that LX& and LXB4 were 
equivalent in this system (fig.1). 
Unlike leukotrienes, which can be metabolized 
by endothelial cells [l], the lipoxins were not fur- 
ther transformed via w-oxidation following ex- 
posure to intact endothelial cells (fig.3). This 
finding indicates that the actions of lipoxins on 
endothelial cells are direct rather than requiring en- 
zymatic transformation in order to express activity. 
Recent results indicate that LX& can block the 
binding of leukotriene D4 to its receptor [18], and 
results have been presented showing that LX& can 
inhibit leukotriene CA-induced responses [ 16,171. 
Taken together, these findings suggest hat lipoxin 
& may act at the receptors for cysteinyl-containing 
leukotrienes in certain tissues. The present findings 
indicate that the action of lipoxins on endothelium 
may involve different receptor mechanisms than in 
other tissues. This is supported by the finding that 
combined addition of maximally stimulatory con- 
centrations of LTC4 and LX& lead to greater pro- 
duction of PGIz than that induced by LTG alone 
(fig.2). 
When exposed to leukotriene &, human 
platelets generate lipoxins and they can be 
generated during platelet-granulocyte interactions 
from endogenous sources of arachidonate [23]. 
Thus, the present finding that lipoxins can 
stimulate prostacyclin generation by human endo- 
thelial cells provides further evidence that lipoxins 
may serve as mediators or modulators of responses 
of interest in inflammation, hemostasis, and 
vascular reactivity. 
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